Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Tarsus Pharmaceuticals (TARS) Equity Income (2021 - 2024)

Historic Equity Income for Tarsus Pharmaceuticals (TARS) over the last 4 years, with Q2 2024 value amounting to -$6000.0.

  • Tarsus Pharmaceuticals' Equity Income fell 14000.0% to -$6000.0 in Q2 2024 from the same period last year, while for Dec 2024 it was -$591000.0, marking a year-over-year decrease of 32818.53%. This contributed to the annual value of -$591000.0 for FY2024, which is 32818.53% down from last year.
  • Latest data reveals that Tarsus Pharmaceuticals reported Equity Income of -$6000.0 as of Q2 2024, which was down 14000.0% from -$585000.0 recorded in Q1 2024.
  • Tarsus Pharmaceuticals' Equity Income's 5-year high stood at $420000.0 during Q4 2023, with a 5-year trough of -$591000.0 in Q4 2021.
  • For the 4-year period, Tarsus Pharmaceuticals' Equity Income averaged around -$108272.7, with its median value being -$65000.0 (2023).
  • As far as peak fluctuations go, Tarsus Pharmaceuticals' Equity Income surged by 62413.79% in 2023, and later tumbled by 80000.0% in 2024.
  • Tarsus Pharmaceuticals' Equity Income (Quarter) stood at -$591000.0 in 2021, then surged by 109.81% to $58000.0 in 2022, then skyrocketed by 624.14% to $420000.0 in 2023, then plummeted by 101.43% to -$6000.0 in 2024.
  • Its Equity Income was -$6000.0 in Q2 2024, compared to -$585000.0 in Q1 2024 and $420000.0 in Q4 2023.